Insider Purchases Signal Confidence: Social media discussions have lit up following reports of substantial insider buying at Larimar Therapeutics, with directors snapping up millions of shares at $5 each shortly after a major public offering. Participants view these moves by key executives as a strong vote of confidence in the biotech firm's pipeline, particularly its lead candidate for Friedreich's ataxia. The purchases, totaling tens of millions, have fueled optimism amid recent volatility.
Dilution Warnings Emerge: Countering the enthusiasm, some voices caution about dilution risks from the company's upsized $100 million offering of 20 million shares, potentially pressuring the stock price. Trackers highlighted active ATM programs and preferred shares convertible into more common stock, sparking debates on long-term shareholder impact. Despite the surge to over $5 post-offering, skeptics warn of a possible pullback.
Breakthrough Designation Boost: Earlier buzz centered on the FDA's Breakthrough Therapy Designation for nomlabofusp, driving a sharp rally and drawing comparisons to sustainability plays, though focused on biotech catalysts. Traders noted high volume and momentum, positioning the stock for potential re-rating. Overall sentiment leans bullish on clinical progress.
Note: This discussion summary was generated from an AI condensation of post data.
Larimar Therapeutics Insider Trading Activity
Larimar Therapeutics insiders have traded $LRMR stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LRMR stock by insiders over the last 6 months:
- JAMES E FLYNN has made 4 purchases buying 5,000,000 shares for an estimated $25,000,000 and 0 sales.
- THOMAS EDWARD HAMILTON purchased 100,000 shares for an estimated $500,000
- JEFFREY W SHERMAN purchased 5,000 shares for an estimated $25,000
- FRANK E THOMAS purchased 5,000 shares for an estimated $25,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Larimar Therapeutics Hedge Fund Activity
We have seen 69 institutional investors add shares of Larimar Therapeutics stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 6,045,351 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $23,032,787
- OPALEYE MANAGEMENT INC. removed 3,720,867 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $14,176,503
- RTW INVESTMENTS, LP added 3,125,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,906,250
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,900,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,137,000
- AIGH CAPITAL MANAGEMENT LLC added 1,000,000 shares (+100.0%) to their portfolio in Q4 2025, for an estimated $3,810,000
- BLUE OWL CAPITAL HOLDINGS LP added 970,650 shares (+16.6%) to their portfolio in Q4 2025, for an estimated $3,698,176
- ALYESKA INVESTMENT GROUP, L.P. removed 959,348 shares (-50.8%) from their portfolio in Q4 2025, for an estimated $3,655,115
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Larimar Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $LRMR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 10/02/2025
- Baird issued a "Outperform" rating on 09/30/2025
- Wedbush issued a "Outperform" rating on 09/30/2025
To track analyst ratings and price targets for Larimar Therapeutics, check out Quiver Quantitative's $LRMR forecast page.
Larimar Therapeutics Price Targets
Multiple analysts have issued price targets for $LRMR recently. We have seen 4 analysts offer price targets for $LRMR in the last 6 months, with a median target of $12.5.
Here are some recent targets:
- Samantha Semenkow from Citigroup set a target price of $14.0 on 02/25/2026
- Laura Chico from Wedbush set a target price of $11.0 on 02/25/2026
- Andreas Argyrides from Oppenheimer set a target price of $21.0 on 10/02/2025
- Joel Beatty from Baird set a target price of $7.0 on 09/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
